NCT02093936

Brief Summary

Background: Induced sputum (IS) is a noninvasive methodology for evaluating airway inflammation in a large number of pulmonary diseases, i.e, Asthma, Chronic obstructive pulmonary disease and Interstitial Lung Diseases. Several studies have defined normal values and cut-off points for this technique based on cellular components of IS, such as percentages of eosinophils, neutrophils, macrophages and CD4/CD8 ratio of T cell lymphocytes. However, normal values and cut-off points for lymphocyte percentages indicative of pathology have not yet been established or validated. This component of IS has considerable clinical value. Similar to other constituents of IS, it can provide biological insights into the pathogenesis of respiratory disorders and contribute to establishing the diagnosis and guiding treatment management of a variety of airway diseases. The purposes of this study are to define normal values and cut-off points of lymphocytes in IS among individuals with respiratory disorders and healthy volunteers, and to verify the current reference values of the percentage of eosinophils, neutrophils and CD4/CD8 ratio in IS. Methods: A Cross Sectional study which includes a database on up to 900 patients who participated in various studies conducted in the Pulmonary Laboratory of Tel Aviv Sourasky Medical Center between 2005 to 2012 will be established. The study population will include patients diagnosed as having various pulmonary diseases and a group of healthy volunteers who will serve as controls. The cut-off for normal values of lymphocyte, eosinophil and neutrophil percentages and CD4/CD8 ratio in IS will be defined by using ROC curves and evaluating sensitivity and specificity. The comparison of the different values to those in the literature will be done by using the Spearman rank correlation. The results of this study will provide supplementary information on lymphocyte counts in IS for identifying and treating various respiratory diseases.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2005

Completed
8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2013

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

March 17, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 21, 2014

Completed
Last Updated

March 21, 2014

Status Verified

March 1, 2014

Enrollment Period

8 years

First QC Date

March 17, 2014

Last Update Submit

March 19, 2014

Conditions

Keywords

airway inflammationinduced sputumnormal valueslymphocyteeosinophilneutrophil

Outcome Measures

Primary Outcomes (1)

  • Healthy patients vs. non-healthy patients

    Healthy patients are those who did not suffer from major respiratory symptoms, were not diagnosed with any pulmonary diseases and had normal pulmonary function tests (i.e, FEV1\>80%, FEV1/FVC ratio\>75%). Non-healthy patients are those who suffered from respiratory symptoms, were diagnosed with a pulmonary disease or had abnormal pulmonary function tests (i.e, FEV1\<80%, FEV1/FVC ratio\<75%).

    1 year

Secondary Outcomes (4)

  • Eosinophil percentage out of all White blood cells in Sputum sample

    Up to 1 day from sputum induction

  • Neutrophil percentage out of all White blood cells in Sputum sample

    Up to 1 day from sputum induction

  • T cell Lymphocyte cluster of differentiation 4 / cluster of differentiation 8 (CD4/CD8) ratio in Sputum sample

    Up to 1 day from sputum induction

  • Lymphocyte percentage out of all White blood cells in Sputum sample

    Up to 1 day from sputum induction

Study Arms (4)

Healthy non exposed

Healthy patients with no pulmonary symptoms that were not exposed to occupational or environmental exposure

Healthy exposed

Healthy patients with no pulmonary symptoms that were exposed to occupational or environmental exposure

Non-healthy exposed

Patients with pulmonary symptoms or diseases that were exposed to occupational or environmental exposure

Non-healthy non-exposed

Patients with pulmonary symptoms or diseases that were not exposed to occupational or environmental exposure

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

People who were sent to the Pulmonology and Allergy Laboratory in the Tel Aviv sourasky medical center between the years 2005-2012. Some had a certain occupational or environmental exposue, some had pulmunary symptoms or diseases and some had both of the above. They were sent in order to examine through spirometry and induced sputum tests wheather they suffer from a pulmonary pathology.

You may qualify if:

  • patients suffering from pulmonary symptoms or diseases
  • patients with occupational or environmental exposure

You may not qualify if:

  • indefinite spirometry tests

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tel Aviv Sourasky medical center

Tel Aviv, Israel, 64239, Israel

Location

Related Publications (5)

  • Balbi B, Pignatti P, Corradi M, Baiardi P, Bianchi L, Brunetti G, Radaeli A, Moscato G, Mutti A, Spanevello A, Malerba M. Bronchoalveolar lavage, sputum and exhaled clinically relevant inflammatory markers: values in healthy adults. Eur Respir J. 2007 Oct;30(4):769-81. doi: 10.1183/09031936.00112306.

    PMID: 17906085BACKGROUND
  • Fireman Z, Osipov A, Kivity S, Kopelman Y, Sternberg A, Lazarov E, Fireman E. The use of induced sputum in the assessment of pulmonary involvement in Crohn's disease. Am J Gastroenterol. 2000 Mar;95(3):730-4. doi: 10.1111/j.1572-0241.2000.01843.x.

    PMID: 10710066BACKGROUND
  • Fireman E, Topilsky I, Greif J, Lerman Y, Schwarz Y, Man A, Topilsky M. Induced sputum compared to bronchoalveolar lavage for evaluating patients with sarcoidosis and non-granulomatous interstitial lung disease. Respir Med. 1999 Nov;93(11):827-34. doi: 10.1016/s0954-6111(99)90269-x.

    PMID: 10603633BACKGROUND
  • Fireman E, Boikaner T, Priel IE. Combined CD4/CD8 ratio in induced sputum and pulmonary function testing for non-invasive identification of sarcoidosis. Transl Res. 2006 Aug;148(2):87-95. doi: 10.1016/j.trsl.2006.03.005.

    PMID: 16890149BACKGROUND
  • Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE, Dolovich J. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 1992 Jan;47(1):25-9. doi: 10.1136/thx.47.1.25.

    PMID: 1539140BACKGROUND

MeSH Terms

Conditions

Respiratory Tract DiseasesOccupational DiseasesDisorders of Environmental Origin

Study Officials

  • Shmuel Kivity, Professor

    Tel-Aviv Sourasky Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
CROSS SECTIONAL
Target Duration
10 Years
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 17, 2014

First Posted

March 21, 2014

Study Start

January 1, 2005

Primary Completion

January 1, 2013

Last Updated

March 21, 2014

Record last verified: 2014-03

Locations